All In Biotech

Drug Trial Radar · NCT04539041

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy

A Randomized, Participant, Investigator and Sponsor Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intrathecally Administered NIO752 in Participants With Progressive Supranuclear Palsy

Last checked: Nov 19, 2026Latest source record: Dec 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

59

Actual

Start

Feb 16, 2021

Primary completion

Oct 17, 2024

Study completion Oct 17, 2024

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1, multi-center, double-blind, placebo-controlled, multiple dose escalation study with NIO752 in progressive supranuclear palsy (PSP) participants.

Conditions

  • Progressive Supranuclear Palsy (PSP)

Interventions

  • antisense oligonucleotideDrug

    solution of antisense oligonucleotide injected intrathecally (spine tap) at multiple dose levels

  • placeboDrug

    placebo for each dose level

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of adverse events and serious adverse eventsTime frame: Baseline up to approximately one year (3-month treatment plus 9-month follow-up or 9-month treatment plus 3-month follow-up)
  2. Change in severity scores for Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Baseline up to approximately 1 year (3-month treatment plus 9-month follow-up or 9-month treatment plus 3-month follow-up)
  3. Levels of infection indicators in Cerebrospinal fluid (CSF)Time frame: Baseline up to approximately 1 year (3-month treatment plus 9-month follow-up or 9-month treatment plus 3-month follow-up)

Locations

12 sites in 4 countries. Site status is shown where the registry gives one.

  • University of California San Diego

    La Jolla, California

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Vanderbilt University Medical CenterX

    Nashville, Tennessee

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Düsseldorf, Germany

  • Novartis Investigative Site

    Hanover, Germany

  • Novartis Investigative Site

    München, Germany

  • Novartis Investigative Site

    Tübingen, Germany

  • Novartis Investigative Site

    Ulm, Germany

  • Novartis Investigative Site

    Bonn, North Rhine-Westphalia, Germany

  • Novartis Investigative Site

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.